Quantitative SPECT is an emerging technology that incorporates standardized uptake values (SUV) and/or activity concentration information to conventional SPECT/CT imaging. In this session we will report on the technical developments that have enabled quantitative SPECT and provide context for understanding its capabilities and limitations. The current role of SPECT/CT for radionuclide treatment planning and external beam treatment planning will be presented through clinical examples with a focus on value and limitations.
1. To learn about the technical developments in terms of acquisition and processing that enabled the evolution of SPECT from qualitative to quantitative imaging
2. To learn about the application of SPECT in radionuclide and external-beam treatment planning
Funding Support, Disclosures, and Conflict of Interest: JD has received research grants from GE Healthcare and served as consultant for GE Healthcare. SCK has received research grants from GE Healthcare, Boston Scientific, ABK Biomedical and has served as a consultant for Sirtex Medical, Boston Scientific, ABK Biomedical.